Articles On EMvision Medical Devices (ASX:EMV)

ASX adds 52 points, hitting a new 50-day high at 8,466.70 points Broad strength with 9 of 11 sectors on the up Gold and finance stocks outperform The ASX was on a roll today, climbing swiftly in the first hour of trade and maintaining mom...

Stockhead’s Tylah Tully looks at the latest from EMvision Medical Devices (ASX:EMV), who have increased the sites for its pivotal trial for the emu bedside brain scanner, a device designed to rapidly diagnose stroke. Watch the video for mor...

AI is reshaping microbiology in the labs Big Pharma taps Clever Culture’s APAS system Here are ASX biotechs with global health deals    Step into a modern microbiology lab today and you might notice something’s different. The culture plat...

ASX health stocks up 0.57% over past week, while the broader market is up 0.35%  Wave of capital raisings as ASX-listed healthcare firms seek to strengthen their balance sheets Monash IVF’s woes continue with company downgrading FY25 blami...

Nanosonics scores FDA De Novo approval in March EMVision is also targeting De Novo for its brain scanner The company’s big potential in the US   When Nanosonics (ASX:NAN) landed FDA De Novo clearance for its CORIS system back in March, th...

Highlights Energy, healthcare and telecommunications sectors drove market advances following a policy rate decision Key gainer Adriatic Metals (ADT) saw takeover talks spark share momentum Regulatory and sales setbacks weigh...

The ASX 200 closed up 0.52% at 8,386 points. Energy was the best performing sector, up1%, followed by Health Care, up 0.95%, and Telecommunication, up 0.88%. Industrials was the worst performer, down 0.52%. In the Green Adriatic...

EMVision Medical Devices advances its AI-driven stroke diagnostics Promising new data shows enhanced performance of ‘ischemia or not’ algorithm Data being presented at 11th European Stroke Organisation Conference   Special Report: EMVisi...

EMVision (ASX:EMV), seeking to disrupt the brain scanner tech space, has sent off a second ‘Emu‘ bedside scanner to a US-based Mayo Clinic site for testing. Shortly to be put to the test in the Jacksonville, Florida Mayo facility; so too...

ASX heath sector falls 2.1%, while broader markets also fall 3.8% for the same period as US tariffs spook global markets Regenerative medicine company Orthocell receives US FDA approval for peripheral nerve repair product Remplir  HealthIn...

ASX heath sector falls 2.1%, while broader markets rise 0.8% for the same period Opthea phase III Coast trial into wet AMD fails to meet primary and secondary endpoints  EMVision starts pivotal validation trial for emu bedside brain scanne...

EMVision starts pivotal validation trial for emu bedside brain scanner to diagnose stroke The first Australian site is the Royal Melbourne Hospital The first US site is the University of Texas Health Science Center at Houston (UTHealth) Me...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

Stockhead joins with IR Department and Morgans for HealthInvest 2025 in Sydney on April 2 Event to highlight some of ASX’s leading up-and-coming health and life sciences companies EMVision, Microba Life Sciences, Orthocell, Lumos Diagnosti...

Highlights ASX 200 sees movement amid global trade shifts and domestic fiscal debates. Corporate governance and renewable energy projects remain key market influences. Mining sector advancements and healthcare innovations sh...

What had been shaping into a solid little Week 13 for the ASX 200 has been pipped at the post heading into Thursday as Australian shares look to follow the global downturn sparked by Trump’s tariffs campaign resurfacing State-side. Liste...

Highlights ASX200 sees a slight upward trend with sector gains. Penny stocks offer unique growth opportunities. Focus on penny stocks with strong financial health. The Australian market recently closed with a mixed performance,...

There are several ASX biotech companies developing drugs to treat complex neurological conditions Global neurological disorder drugs market size set to reach US$149.17 billion by 2032 Petra Capital’s Tanushree Jain says neurological disord...

ASX health stocks break losing streak, up 1.78% over past week, while the broader market rises 2.01% Nanosonics receives US FDA De Novo clearance for its flexible endoscope cleaning system Coris Sigma’s full-year FY25 results as a stand al...

TBI awareness month highlights need for better care ASX companies roll out devices to tackle TBI head-on From portable scanners to life-changing tech, TBI solutions are evolving   March is Traumatic Brain Injury (TBI) Awareness Month, a...

EMVision Medical Devices (ASX: EMV) has completed aeromedical retrieval environment testing of its First Responder proof-of-concept (PoC) device to treat rural patients with stroke and traumatic brain injury (TBI). The company used the worl...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Tylah Tully gives the skinny on EMVsion Medical Devices’ (ASX:EMV)  latest advancement of its ‘First Responder’ proof-of-concept device,...

Emvision to launch remote stroke detection trial It’s a tricky market but biotechs are raising funds Imugene wins FDA fast-track status for cancer program   Ahead of a wider trial, Emvision Medical Devices (ASX:EMV) has taken to the air w...

  EMVision is transitioning from R&D stage to commercialisation with its portable brain scanners to diagnose stroke First 60 minutes after a stroke is known as ‘the golden hour’ and is particularly critical for positive outcomes Pivot...

  EMVision is moving from R&D stage to commercialisation with its portable brain scanner to detect stroke First 60 minutes after a stroke is known as ‘the golden hour’ and can determine outcomes Pivotal trial for US FDA approval of EMU...

Highlights  Ceretas secures $1 million to further develop its breakthrough ultrasound therapy for dementia.  Backed by leading investors and strong philanthropic support, the company progresses toward clinical trials.  The technology...

Highlights Australian penny stocks show growth potential amid market volatility EMVision (EMV), Praemium (PPS), and Wagners Holding (WGN) demonstrate strong financial profiles The Reserve Bank's upcoming rate decision creates a dynami...

The ASX200 has been up 0.25% at 8,505 points. Industrials has been the strongest performing sector, up 1.6%, followed by Financials, up 1.07%, and Staples, up 0.92%. IT has been the worst-performing sector, down 1.63, followed by Heal...

It’s starting to look like a flat Wednesday, with Aussie futures now pointing to a near-unnoticeable 0.03% drop for the bourse at open today. We finally got Federal Reserve chairman Jerome Powell’s latest stance on cuts in the U.S. overn...

Having lodged their paperwork, companies including EBR Systems, Artyra and Orthocell await crucial FDA approval The agency has improved its communications with applicants, which avoids nasty surprises Applicants are doing the commercial gr...

ASX 200 drops as gold, iron ore and energy stocks struggle Paladin shares plunge after cutting uranium output forecast Australian business confidence hits two-year high amid easing inflation   The ASX 200 index slipped by 0.13% on Tuesday...

Emvision expects to release trial results for its Emu stroke-detection device in November Syntara’s rare blood cancer program gathers pace Actinogen says 25 patients have been treated in its 200-candidate Alzheimer’s disease study   Quart...

In this interview Dale Gillham and small cap company director Rod North discuss what to look for in microcap stocks and what place they should have in an investor’s portfolio. They discuss success stories, risk vs reward, and, the challe...

Nyrada to launch phase I first-in-human trial after passing preclinical safety studies Neuren Pharmaceuticals ‘mini me’ Percheron seeks funds for rare disease program Another win for Pro Medicus, this time locally   Nyrada (ASX:NYR) share...

Curvebeam’s innovative products are revolutionising cone beam CT imaging The company’s HiRise offers weight-bearing CT scans directly to a surgeon’s office The enhanced HiRise has recently received FDA clearance   The medical devices segm...

Founder-led medical technology company EMVision (ASX: EMV) has today unveiled its proof of concept device for a backpack-sized brain scanner to be used by first responders, which if successfully commercialised would allow paramedics to scan...

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

Stage 2 interim data from a pre-validation trial by EMVision Medical Devices (ASX: EMV) has confirmed the positive performance of neurodiagnostic artificial intelligence (AI) algorithms in the diagnosis of suspected haemorrhagic or ischaemi...

EMVision’s AI algorithm shows promise EMvision Medical Devices (ASX:EMV) has shared an update from its ongoing clinical trials focusing on improving EMVision’s AI algorithms for diagnosing strokes caused by bleeding or blockages in the brai...

    ASX 200 set to rise Monday, following New York’s rally US traders optimistic after Michigan survey, easing inflation concerns Approval for Ether ETFs opens door for Blackrock, VanEck, and Ark 21Shares   The ASX 200 is poised to rebou...

Australian company EMVision Medical Devices (ASX:EMV) has secured a strategic $15.28 million investment via a placement to the long-standing investor in the company, Keysight Technologies.

EMvision receives strategic investment from NYSE-listed firm Radiopharm doses first patient in Phase 1 pancreatic cancer trial   EMVision receives investment from NYSE-listed Keysight EMVision Medical Devices (ASX:EMV) soared as high as 1...

  ASX to open lower, tracking Wall Street Fed member sees rate cuts this year as inflation data looms Bitcoin pops to over US$60k, with more catalysts to come   The ASX is poised to open lower on Thursday in line with losses on Wall Stre...

So much for a small rise on the market today. Instead, the ASX200 closed down about three quarters (.76) per cent. Real estate stocks proved the biggest drag, down just over one and a quarter of a per cent, while IT was the only sector t...

The ASX200 has been trading down more than .4 per of a per cent today.    Information technology is the only sector in the green, adding nearly a per cent, while consumer discretionary is the poorest performer so far, down nearly 1.2 per...

EMVision (ASX:EMV) reveals the name of its inaugural point-of-care brain scanner device, ’emu’, at the RSNA 2023 conference In parallel, the company has fully recruited 150 suspected stroke patients for stage two of its multi-site clinic...

ASX medical devices to make inroads with FDA after a good year for drug developers FDA is reviewing Allegra’s Spinal Cage Device made from 3D-printed Sr-HT-Gahnite Stockhead reached out to Allegra’s board member, Dr Nick Hartnell   It’s b...

EMVision Medical Devices (ASX:EMV) assembles an advanced 28-antenna prototype for its second-generation helmet scanner The ultra-lightweight helmet scanner is designed for use in road and air ambulance settings An ethics submission fo...

Recce Pharma moves forward to stronger dose in Phase 1/2 trial EMV is bench testing its 2nd Gen ultra-light weight helmet scanner   Recce Pharma moves forward to higher dosage Synthetic anti-infectives producer, Recce Pharmaceuticals (ASX...

Paradigm Biopharma set to submit application to TGA EMVision uses artificial intelligence simulation   Paradigm to submit TGA application after successful trial Paradigm Biopharmaceuticals (ASX:PAR) jumped 13% this morning after reporting...